Many microbiology laboratories, including my own, have in place a CSF leucocyte count cut-off of 5 × 10⁶/L as a criterion for performing multiplex PCR in the investigation of meningoencephalitis. This diagnostic stewardship policy has attempted to focus testing on those most likely to have CNS infection, and to reduce unnecessary testing. However, growing evidence indicates that this approach is not appropriate when there is clinical suspicion of encephalitis…
Take this hypothetical case study…
A 58-year-old man, Mr J Bloggs, presents with fever, headache, confusion and a vague history of what could be a focal seizure. MRI was unremarkable. A lumbar puncture is performed within eight hours of presentation. The CSF shows a white cell count of 4 × 10⁶/L, normal glucose, and mildly elevated protein. Under existing laboratory policy, the CSF multiplex PCR panel is not performed because the leucocyte count is below 5 × 10⁶/L. Empirical acyclovir therapy is discontinued on the basis of the normal CSF leucocyte count. However, the diagnosis remained uncertain and persistent symptoms prompted a repeat CSF several days later. HSV-1 DNA is detected by PCR on the second CSF sample.
CSF analysis is excellent for detecting meningeal inflammation, as occurs in meningitis, but it is less reliable for parenchymal infection, which characterises encephalitis. In encephalitic processes, inflammation may be largely confined to the brain parenchyma, without a corresponding CSF pleocytosis, especially early in the disease. Leucocyte thresholds designed for meningitis are therefore poorly suited to encephalitis and potentially risk giving false reassurance.
Recent evidence has demonstrated that a substantial proportion of patients with encephalitis have normal CSF leucocyte counts. The most compelling data to date come from a recent large retrospective study by Habis et al., involving 597 adult patients with encephalitis. They found that 25.3% had no CSF pleocytosis (<5 × 10⁶/L). Among those with infectious encephalitis, 19% lacked pleocytosis, and notably, 23.7% of HSV-1 encephalitis cases had normal CSF cell counts at presentation. Patients without pleocytosis were also less likely to receive empiric acyclovir, showing how laboratory thresholds influence clinical care. These findings strongly challenge the validity of using a fixed leucocyte cut-off to determine whether PCR testing should be performed, as it would exclude roughly one in four encephalitis patients, including many with HSV infection.
In addition, and as also shown by Habis et al., patients without pleocytosis are less likely to receive prompt antiviral therapy. This matters because early treatment, particularly for HSV encephalitis, improves outcomes. Diagnostic stewardship should promote timely, appropriate testing, not create barriers based on outdated assumptions…
Laboratory protocols should always be responsive to new data. When high-quality evidence emerges that challenges existing practice, policies must be reviewed and revised. While a 5 × 10⁶/L CSF leucocyte threshold may remain reasonable in the investigation of suspected meningitis, it is no longer valid in the setting of suspected encephalitis, where pleocytosis may be absent in a substantial proportion of cases. Stewardship frameworks should incorporate these distinctions, and most importantly, allow flexibility in order to optimise patient safety.
Laboratory practice must evolve with emerging data to ensure that diagnostic stewardship supports, rather than hinders, accurate and timely diagnosis. I am a diagnostic stewardship enthusiast, but I am the first to admit that we don’t get it right all the time.
Michael
p.s. Check out this great editorial on this topic!
References